Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Journal of the American Chemical Society|July 27, 2006
Fast local backbone dynamics of encapsulated ubiquitinAlana K Simorellis, Peter F FlynnJournal of Magnetic Resonance (San Diego, Calif. : 1997)|September 25, 2004
A PFG NMR experiment for translational diffusion measurements in low-viscosity solvents containing multiple resonancesAlana K Simorellis, Peter F FlynnJournal of the American Chemical Society|September 30, 2005
Low-temperature studies of encapsulated proteinsWade D Van Horn, Alana K Simorellis, Peter F FlynnJournal of the American Chemical Society|April 13, 2006
Dynamics of low temperature induced water shedding from AOT reverse micellesAlana K Simorellis, Wade D Van Horn, Peter F FlynnBiochemistry|April 16, 2009
Redox-dependent dynamics in cytochrome P450camSusan Sondej Pochapsky, Marina Dang, Bo OuYang, et al.Biophysical Journal|March 6, 2012
A delicate interplay of structure, dynamics, and thermodynamics for function: a high pressure NMR study of outer surface protein ARyo Kitahara, Alana K Simorellis, Kazumi Hata, et al.Journal of Inorganic Biochemistry|November 21, 2007
Hydrogen-deuterium exchange mass spectrometry for investigation of backbone dynamics of oxidized and reduced cytochrome P450camYoshitomo Hamuro, Kathleen S Molnar, Stephen J Coales, et al.Respiratory Investigation|September 10, 2024
Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trialDavid Fitz-Patrick, Hanako Mihara, Anthony Mills, et al.The Journal of Infectious Diseases|February 22, 2024
Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older AdultsChristine A Shaw, Brandon Essink, Charles Harper, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 24, 2025
Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 YearsJaya Goswami, Jose F Cardona, Jorge Caso, et al.Pageof 2